

Special Issue

Advances in the Genetics of Plasma Cholesterol Levels

Message from the Guest Editor

In 1965, Fredrickson and Lees established the most widely used system to classify hyperlipidemic phenotypes, defining all of them as “familial”, which implied the idea of a Mendelian inheritance of genetic variants with a great phenotypic effect. Genome-wide association studies have identified the existence of common genetic variants at various loci associated with plasma cholesterol level, which could explain the most common forms of hypercholesterolemia through processes such as the accumulation in an individual, or gene–gene and gene–environment interactions. In this Special Issue, we aim to collect recent advances in the genetic determinants of plasma cholesterol levels, especially related to the development of hyper- and hypocholesterolemia, which includes the identification of new genes, the identification of polygenic forms through scoring systems and their possible application in genetic diagnosis, and the possible existence of complex forms due to gene–gene and gene–environment interactions.

Guest Editor

Dr. Jesus M. Martin-Campos

Santa Creu i Sant Pau Hospital Research Institute– IIB-Sant Pau,
Barcelona, Spain

Deadline for manuscript submissions

closed (31 October 2021)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 7.8
Indexed in PubMed



mdpi.com/si/70821

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 7.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA

2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.2 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2026).